Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B.
BMJ Case Rep
; 13(5)2020 May 12.
Article
in English
| MEDLINE | ID: covidwho-822228
ABSTRACT
Critically ill patients are at risk of developing both acute kidney injury (AKI) and invasive fungal infections (IFIs). Prompt and efficient treatment of the IFI is essential for the survival of the patient. This article examines three distinct clinical situations where liposomal amphotericin B, a broad-spectrum antifungal agent, was successfully used in the setting of AKI. The first was Aspergillus infection in a 63-year-old man with bleeding oesophageal varices related to advanced liver disease. The second was gastrointestinal mucormycosis in a 74-year-old man who developed a small bowel obstruction following an autologous stem cell transplant for mantle cell lymphoma. The third was a Fusarium infection in a 32-year-old woman on immunosuppression for a bilateral lung transplant for cystic fibrosis. In all three cases, liposomal amphotericin B was required for urgent management of the patient's IFI. We discuss the rationale for treatment with a potentially nephrotoxic agent in this setting.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Amphotericin B
/
Critical Illness
/
Acute Kidney Injury
/
Invasive Fungal Infections
/
Antifungal Agents
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Year:
2020
Document Type:
Article
Affiliation country:
Bcr-2019-233072
Similar
MEDLINE
...
LILACS
LIS